Skip to main content
search
El MAFLD como factor de riesgo para cáncer hepatocelular
GastroenterologíaGastroenterología - La obesidad es una enfermedadGastroenterología - Obesidad

El MAFLD como factor de riesgo para cáncer hepatocelular

By febrero 9, 2023No Comments

Estimado (a) Dr. (a.),

La enfermedad del hígado graso asociada a la disfunción metabólica (MAFLD) se ha convertido en la causa más frecuente de hepatopatía crónica y condiciona casi el doble de casos como causa de cirrosis hepática en relación con el virus de la hepatitis C; México no está exento de esto, se estima que en la siguiente década se convertirá en la principal causa de trasplante hepático en el mundo. (¹,²)

En la siguiente infografía, el Dr. Genaro Vázquez Elizondo nos muestra sobre “El MALFD como factor de riesgo para cáncer hepatocelular”, material de gran actualidad y dimensión, dejando claro la trascendencia que actualmente conlleva la obesidad y el MALFD como factores de riesgo para el desarrollo de carcinoma hepatocelular.

 

Referencias:

  1. Marengo A, Rosso C, Bugianesi E. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annu Rev Med. 2016 Oct [cited 2022 Feb 21];67:103-17. Available from: https://pubmed.ncbi.nlm.nih.gov/26473416/.
  2. Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol. 2020 May [cited 2022 Feb 21];17(7):387-8. Available from: https://pubmed.ncbi.nlm.nih.gov/32461575/.
  3. Sanyal A J, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006 Apr [cited 2022 Feb 21];43(4):682-9. Available from: https://pubmed.ncbi.nlm.nih.gov/16502396/.
  4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough A J, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999 Nov [cited 2022 Feb21];107(5):450-5. Available from: https://pubmed.ncbi.nlm.nih.gov/10569299/.
  5. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun [cited 2022 Feb 21];55(6):2005-23. Available from: https://pubmed.ncbi.nlm.nih.gov/22488764/.
  6. Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019 Mar [cited 2022 Feb 21];70(3):531-44. Available from: https://pubmed.ncbi.nlm.nih.gov/30414863/.
  7. Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020 Aug [cited 2022 Feb 21];21(16). Available from: https://pubmed.ncbi.nlm.nih.gov/32824337/.
  8. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009 Nov [cited 2022 Feb 22];24(2):248-54. Available from: https://pubmed.ncbi.nlm.nih.gov/19032450/.
  9. Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, et al. The Mexican consensus on nonalcoholic fatty liver disease. Rev Gastroenterol Mex (Engl Ed). 2019 Jan-Mar [cited 2022 Feb 22];84(1):69-99. Available from: https://pubmed.ncbi.nlm.nih.gov/30711302/.
  10. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021 Apr [cited 2022 Feb 22];18(4):223-38. Available from: https://pubmed.ncbi.nlm.nih.gov/33349658/.
  11. Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 2021 May [cited 2022 Feb 23];3(4):100305. Available from: https://pubmed.ncbi.nlm.nih.gov/34189448/.
  12. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol. 2016 Jun [cited 2022 Feb 23];64(6):1388-402. Available from: https://pubmed.ncbi.nlm.nih.gov/27062661/.
  13. Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol. 2018 Feb [cited 2022 Feb 23];68(2):326-34. Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(17)32353-X/pdf.

 

 

Para descargar la infografía en PDF haga click aquí.

 

Material desarrollado con fines de educación médica continua.

Material exclusivo para profesionales de la salud.

La información aquí presentada es opinión del ponente.

Código interno: MX22SX00162.

Leave a Reply

Close Menu